HLA-Class II Artificial Antigen Presenting Cells in CD4

Antigen Presentation Antigen-Presenting Cells / immunology CD4-Positive T-Lymphocytes / immunology Cancer Vaccines / immunology Cell Proliferation HLA Antigens / metabolism Histocompatibility Antigens Class II / metabolism Humans Immunotherapy, Adoptive / methods T-Lymphocytes, Regulatory / immunology
CD4+ T lymphocytes HLA class II molecules adoptive cell therapy artificial antigen presenting cells autoimmunity cancer

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 10 01 2019
accepted: 29 04 2019
entrez: 4 6 2019
pubmed: 4 6 2019
medline: 2 10 2020
Statut: epublish

Résumé

CD4

Identifiants

DOI: 10.3389/fimmu.2019.01081 PMID: 31156634 PMC: PMC6533590
pubmed: 31156634
doi: 10.3389/fimmu.2019.01081
pmc: PMC6533590
doi:

Substances chimiques

Cancer Vaccines 0
HLA Antigens 0
Histocompatibility Antigens Class II 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1081

Références

Science. 1999 Jul 9;285(5425):221-7
pubmed: 10398592
Nat Biotechnol. 2000 Apr;18(4):405-9
pubmed: 10748520
J Immunol. 2001 Aug 1;167(3):1313-24
pubmed: 11466348
J Exp Med. 2001 Dec 17;194(12):1711-9
pubmed: 11748273
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
J Immunol. 2002 May 15;168(10):4897-906
pubmed: 11994439
J Exp Med. 2002 Aug 5;196(3):389-99
pubmed: 12163567
J Immunol. 2002 Sep 1;169(5):2461-5
pubmed: 12193715
Science. 2002 Sep 20;297(5589):2060-3
pubmed: 12242444
J Immunol. 2002 Nov 1;169(9):4850-60
pubmed: 12391195
Science. 2002 Nov 22;298(5598):1630-4
pubmed: 12446913
Nature. 2003 Feb 20;421(6925):852-6
pubmed: 12594515
Blood. 2003 Oct 1;102(7):2498-505
pubmed: 12805061
Lancet. 2003 Oct 25;362(9393):1375-7
pubmed: 14585640
Blood. 2004 Jul 15;104(2):453-61
pubmed: 15031211
J Exp Med. 2004 Jun 7;199(11):1455-65
pubmed: 15184499
Nat Immunol. 2004 Sep;5(9):927-33
pubmed: 15300249
Br J Ophthalmol. 2004 Oct;88(10):1280-4
pubmed: 15377551
Nature. 2005 Mar 3;434(7029):88-93
pubmed: 15744305
J Immunol. 2005 Sep 1;175(5):3025-32
pubmed: 16116190
J Immunol. 2005 Nov 1;175(9):6177-89
pubmed: 16237115
Int Immunol. 2005 Dec;17(12):1561-72
pubmed: 16303787
Nature. 2006 Apr 13;440(7086):890-5
pubmed: 16612374
Transplantation. 2006 May 27;81(10):1390-7
pubmed: 16732175
Nature. 2006 Jun 15;441(7095):890-3
pubmed: 16778891
Nat Med. 2006 Dec;12(12):1397-402
pubmed: 17115047
J Immunol. 2006 Dec 15;177(12):8338-47
pubmed: 17142730
Int Immunol. 2007 Jun;19(6):713-8
pubmed: 17548342
Int Immunol. 2007 Oct;19(10):1191-9
pubmed: 17698559
Blood. 2008 Jan 15;111(2):715-22
pubmed: 17932250
Blood. 2008 Jul 15;112(2):362-73
pubmed: 18354038
J Immunol. 2008 Apr 1;180(7):4570-6
pubmed: 18354179
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5201-6
pubmed: 18362335
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9331-6
pubmed: 18599457
J Immunol. 2008 Sep 15;181(6):3933-46
pubmed: 18768848
Clin Exp Immunol. 2009 Apr;156(1):149-60
pubmed: 19210524
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Clin Immunol. 2009 Oct;133(1):22-6
pubmed: 19559653
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Clin Cancer Res. 2010 Jan 1;16(1):338-47
pubmed: 20048335
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
Immunology. 2010 Jul;130(3):418-26
pubmed: 20465565
J Immunol. 2010 Jun 15;184(12):6629-36
pubmed: 20483764
J Exp Med. 2010 Aug 30;207(9):1871-8
pubmed: 20679400
J Transl Med. 2010 Oct 26;8:104
pubmed: 20977748
Int Immunol. 2010 Nov;22(11):863-73
pubmed: 21059769
J Immunol. 2010 Dec 15;185(12):7302-8
pubmed: 21076058
Nat Rev Immunol. 2010 Dec;10(12):849-59
pubmed: 21107346
Clin Infect Dis. 2011 Jan 1;52(1):49-57
pubmed: 21148519
Nat Immunol. 2011 Mar;12(3):255-63
pubmed: 21278737
J Immunol. 2011 Apr 1;186(7):4415-21
pubmed: 21346235
Nat Immunol. 2011 Jun;12(6):568-75
pubmed: 21516111
Clin Cancer Res. 2011 Aug 15;17(16):5392-401
pubmed: 21705450
Nat Immunol. 2011 Jul 31;12(9):908-13
pubmed: 21804558
Nat Rev Immunol. 2012 Jan 20;12(2):136-48
pubmed: 22266691
Diabetes. 2012 Oct;61(10):2534-45
pubmed: 22688334
Nat Med. 2012 Aug;18(8):1248-53
pubmed: 22772464
Mol Ther. 2012 Aug;20(8):1622-32
pubmed: 22801446
PLoS One. 2012;7(9):e45299
pubmed: 23028916
J Neurol Sci. 2013 Oct 15;333(1-2):43-9
pubmed: 23294498
Nat Immunol. 2013 Apr;14(4):372-9
pubmed: 23475182
Nat Immunol. 2013 Apr;14(4):307-8
pubmed: 23507634
Front Oncol. 2013 Mar 26;3:63
pubmed: 23533029
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633-7
pubmed: 2377601
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Nat Commun. 2013;4:2039
pubmed: 23783831
Blood. 2013 Aug 22;122(8):1419-27
pubmed: 23847198
Front Immunol. 2013 Aug 29;4:260
pubmed: 24009612
Immunity. 2013 Oct 17;39(4):744-57
pubmed: 24138883
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a016873
pubmed: 24296169
Immunol Rev. 2014 Jan;257(1):191-209
pubmed: 24329798
J Hematol Oncol. 2013 Dec 17;6:94
pubmed: 24341630
Front Immunol. 2013 Dec 16;4:464
pubmed: 24379819
Sci Transl Med. 2014 Jan 15;6(219):219ra8
pubmed: 24431112
Immunol Rev. 2014 Mar;258(1):12-29
pubmed: 24517423
J Immunol. 2014 Apr 1;192(7):3111-20
pubmed: 24610014
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Ann Clin Lab Sci. 2014 Spring;44(2):180-8
pubmed: 24795057
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Nat Immunol. 2014 Jul;15(7):676-86
pubmed: 24908389
Nat Immunol. 2014 Aug;15(8):758-66
pubmed: 24973819
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
J Dermatol Sci. 2015 Jun;78(3):206-14
pubmed: 25840641
Cell Mol Immunol. 2015 Sep;12(5):566-71
pubmed: 26051475
Cancer Res. 2015 Sep 1;75(17):3446-55
pubmed: 26060019
Nat Med. 2015 Oct;21(10):1216-22
pubmed: 26413780
Nat Commun. 2015 Oct 05;6:8437
pubmed: 26436530
Blood. 2016 Feb 25;127(8):1044-51
pubmed: 26563133
Sci Transl Med. 2015 Nov 25;7(315):315ra189
pubmed: 26606968
Gut. 2017 Mar;66(3):454-463
pubmed: 26681737
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
Nat Rev Immunol. 2016 Mar;16(3):149-63
pubmed: 26875830
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Immunol Cell Biol. 2016 Aug;94(7):662-72
pubmed: 26924643
Nat Commun. 2016 Mar 15;7:10991
pubmed: 26975663
J Clin Invest. 2016 Apr 1;126(4):1413-24
pubmed: 26999600
Sci Rep. 2016 Apr 05;6:24072
pubmed: 27044888
Blood. 2016 Jul 7;128(1):130-7
pubmed: 27073224
Annu Rev Immunol. 2016 May 20;34:317-34
pubmed: 27168241
Blood. 2016 Jun 30;127(26):3331-40
pubmed: 27207801
J Transl Med. 2016 Aug 02;14(1):230
pubmed: 27484705
Semin Immunopathol. 2017 Jan;39(1):47-54
pubmed: 27896634
Annu Rev Immunol. 2017 Apr 26;35:53-84
pubmed: 27912316
Am J Transplant. 2017 Apr;17(4):931-943
pubmed: 28027623
Front Immunol. 2017 Jan 19;8:20
pubmed: 28154568
Methods Mol Biol. 2017;1585:73-82
pubmed: 28477188
Nat Rev Immunol. 2017 Sep;17(9):535-544
pubmed: 28555673
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cytokine Growth Factor Rev. 2017 Oct;37:47-55
pubmed: 28739029
Haematologica. 2017 Nov;102(11):1833-1841
pubmed: 28751567
J Clin Oncol. 2017 Nov 1;35(31):3547-3557
pubmed: 28783452
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Nat Commun. 2017 Oct 9;8(1):815
pubmed: 28993609
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Brain. 2018 May 1;141(5):1334-1349
pubmed: 29659729
Cancer Cell. 2018 Jun 11;33(6):1048-1060.e7
pubmed: 29894691
Nat Immunol. 2018 Jul;19(7):665-673
pubmed: 29925983
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Eur J Clin Invest. 2019 Jan;49(1):e13032
pubmed: 30289986
Ann Rheum Dis. 2019 Feb;78(2):209-217
pubmed: 30472651
Nat Immunol. 2019 Apr;20(4):458-470
pubmed: 30890796

Auteurs

Alexandre Couture (A)

UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France.

Anthony Garnier (A)

Inserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, France.

Fabian Docagne (F)

Inserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, France.

Olivier Boyer (O)

Department of Immunology and Biotherapy, Inserm U1234, Institute for Research and Innovation in Biomedicine, UNIROUEN, Rouen University Hospital, Normandie University, Rouen, France.

Denis Vivien (D)

Inserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, France.
Department of Clinical Research, Caen University Hospital, Caen, France.

Brigitte Le-Mauff (B)

Inserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, France.
Department of Immunology and Immunopathology, Caen University Hospital, Caen, France.

Jean-Baptiste Latouche (JB)

UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, France.
Department of Genetics, Rouen University Hospital, Rouen, France.

Olivier Toutirais (O)

Inserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, France.
Department of Immunology and Immunopathology, Caen University Hospital, Caen, France.
French Blood Service (Etablissement Français du Sang), Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité cellulaire › Présentation d'antigène › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Cellules présentatrices d'antigène › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins anticancéreux › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe II › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › HLA-Class II Artificial Antigen Presenting Cells in CD4
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › HLA-Class II Artificial Antigen Presenting Cells in CD4